國立虎尾科技大學 |

PI3K-mTOR in Cancer and Cancer Therapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	PI3K-mTOR in Cancer and Cancer Therapy/ edited by Nandini Dey, Pradip De, Brian Leyland-Jones.
其他作者:	Dey, Nandini.
面頁冊數:	XXIV, 294 p. 31 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-319-34211-5
ISBN:	9783319342115

PI3K-mTOR in Cancer and Cancer Therapy
PI3K-mTOR in Cancer and Cancer Therapy[electronic resource] /edited by Nandini Dey, Pradip De, Brian Leyland-Jones. - 1st ed. 2016. - XXIV, 294 p. 31 illus. in color.online resource. - Cancer Drug Discovery and Development,2196-9906. - Cancer Drug Discovery and Development,.

PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities.

In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway’s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.

ISBN: 9783319342115

Standard No.: 10.1007/978-3-319-34211-5doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

PI3K-mTOR in Cancer and Cancer Therapy
LDR:03702nam a22004095i 4500 001 977307
003 DE-He213
005 20200704233146.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319342115 $9 978-3-319-34211-5
024 7 $a 10.1007/978-3-319-34211-5 $2 doi
035 $a 978-3-319-34211-5
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a PI3K-mTOR in Cancer and Cancer Therapy $h [electronic resource] / $c edited by Nandini Dey, Pradip De, Brian Leyland-Jones.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2016.
300 $a XXIV, 294 p. 31 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Cancer Drug Discovery and Development, $x 2196-9906
505 0 $a PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities.
520 $a In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway’s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.
650 0 $a Cancer research. $3 1253664
650 0 $a Molecular biology. $3 583443
650 0 $a Drug resistance. $3 872072
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
650 2 4 $a Drug Resistance. $3 782695
700 1 $a Dey, Nandini. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1110750
700 1 $a De, Pradip. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1110751
700 1 $a Leyland-Jones, Brian. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 778266
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319342092
776 0 8 $i Printed edition: $z 9783319342108
776 0 8 $i Printed edition: $z 9783319817040
830 0 $a Cancer Drug Discovery and Development, $x 2196-9906 $3 1253870
856 4 0 $u https://doi.org/10.1007/978-3-319-34211-5
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)